Saana Palomurto

Saana Palomurto

Auto-generated profile, based on publicly available information

Saana Palomurto

Department of Surgery Kuopio University Hospital, North Savo Wellbeing County Kuopio Finland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Digestive and Liver Disease
Verified
Journal Article
Open access
ABAmbrin Farizah Babu
Ambrin Farizah Babu
SPSaana Palomurto
Saana Palomurto
VKVesa Kärjä
Vesa Kärjä
PKPirjo Käkelä
Pirjo Käkelä
MLMarko Lehtonen
Marko Lehtonen
VMVille Männistö
Ville Männistö
Metabolic dysfunction-associated steatotic liver disease (MASLD) can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Still, most patients with MASLD die from cardiovascular diseases indicating metabolic alterations related to both liver and cardiovascular pathology. The aim of this study was to assess biologic pathways behind MASLD progression from steatosis to metabolic dysfunction-associated steatohepatitis (MASH) using non-targeted liquid chromatography-mass spectrometry analysis in 106 severely obese individuals (78 women, mean age 47.7 7 ± 9.2 years, body mass index 41.8 ± 4.3 kg/m²) undergoing laparoscopic Roux-en-Y gastric bypass. We identified several metabolites that are associated with MASLD progression. Most importantly, we observed a decrease of lysophosphatidylcholines LPC(18:2), LPC(18:3), and LPC(20:3) and increase of xanthine when comparing those with steatosis to those with MASH. We found that indole propionic acid and threonine were negatively correlated to fibrosis, but not with the metabolic disturbances associated with cardiovascular risk. Xanthine, ketoleucine, and tryptophan were positively correlated to lobular inflammation and ballooning but also with insulin resistance, and dyslipidemia, respectively. The results did not change when taking into account the most important genetic risk factors of MASLD. Our findings suggest that there are several separate biological pathways, some of them independent of insulin resistance and dyslipidemia, associating with MASLD.

12 June 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
SPSaana Palomurto
Saana Palomurto
KVKirsi A Virtanen
Kirsi A Virtanen
VKVesa Kärjä
Vesa Kärjä
USUrsula Schwab
Ursula Schwab
DKDorota Kaminska
Dorota Kaminska
VMVille Männistö
Ville Männistö
Context: The alterations in systemic fatty acid (FA) metabolism in metabolic dysfunction-associated steatotic liver disease (MASLD) remain unclear. Objective: To investigate intertissue crosstalk in FA metabolism in patients with MASLD, we compared FA profiles in the liver, serum, visceral, and subcutaneous adipose tissue of patients with severe obesity and normal liver, simple steatosis, or metabolic dysfunction-associated steatohepatitis (MASH). Methods: Preoperative serum, liver, subcutaneous, and visceral adipose tissue samples were collected during laparoscopic gastric bypass surgery from 183 patients with severe obesity (122 women, mean age 46.9 ± 9.7 years, body mass index 43.5 ± 5.7 kg/m2). FA composition was analyzed using gas-liquid chromatography. The Kruskal–Wallis test was used to compare the FA proportions in different tissue depots. Results: FA proportions varied more in the liver than in adipose tissue in patients with MASH. Polyunsaturated FAs (PUFA) proportions were significantly lower in the livers of patients with MASH than in those with normal livers (all adjusted P < .01). Conversely, dihomo-gamma-linolenic acid, adrenic acid, and arachidonic acid proportions were higher in the adipose tissues of patients with MASH (all adjusted P < .001). Conclusion: Patients with MASH exhibited reduced hepatic PUFA content, increased hepatic saturated FAs, and a higher n6-to-n3 PUFA ratio, whereas no clear trends were observed in adipose tissue. These findings highlight distinct differences in FA metabolism between the liver and adipose tissue in MASLD, emphasizing tissue-specific regulatory mechanisms.

12 February 2026 in Liver International
Verified
Journal Article
Open access
SPSaana Palomurto
Saana Palomurto
EFEmily Flam
Emily Flam
DKDorota Kaminska
Dorota Kaminska
KVKirsi A. Virtanen
Kirsi A. Virtanen
VKVesa Kärjä
Vesa Kärjä
VMVille Männistö
Ville Männistö
Background and Aims: Metabolic dysfunction‐associated steatotic liver disease (MASLD), the most common chronic liver disease worldwide, is closely linked to obesity and metabolic syndrome. The reason some patients with MASLD develop metabolic dysfunction‐associated steatohepatitis (MASH) and which metabolic changes in the liver are linked to its progression are unclear. Methods: A non‐targeted metabolomics analysis was performed on liver samples from 106 Finnish patients with severe obesity (71 females, mean age ± SD: 48.6 ± 8.7 years, body mass index: 41.6 ± 5.2 kg/m 2 ) selected for laparoscopic gastric bypass surgery. Liver metabolomics and liver RNA sequencing data were used to study metabolic differences between those with steatosis and those with MASH. Validation was performed in a French cohort of 227 patients with obesity and MASLD. Results: Overall, 45 metabolites differed between patients with steatosis and those with MASH. Novel MASH‐associated metabolites included n ‐acetylneuraminate ( β = 0.276), pentose acid ( β = −0.290), UDP‐galactose ( β = −0.413), gamma/beta‐tocopherol ( β = −0.317), and guanidinosuccinate ( β = −0.289) (all p < 0.05). In the validation cohort, 8 of 20 metabolites, including n ‐acetylneuraminate and plasmalogens 1‐(1‐enyl‐palmitoyl)‐2‐arachidonoyl‐GPE(P‐16:0/20:4) and 1‐(1‐enyl‐stearoyl)‐2‐arachidonoyl‐GPE(P‐18:0/20:4), were linked to MASH ( p < 0.05). The 45 significantly altered metabolites formed two clusters with different associations with metabolic parameters, depending on their correlation with liver histological features. Kyoto Encyclopedia of Genes and Genomes analysis revealed that elevated metabolites in MASH were associated with inflammatory pathways; those decreased in MASH were linked to fatty acid degradation and amino acid and pyruvate metabolism. Conclusion: Transitioning from simple steatosis to MASH is associated with distinct alterations in liver metabolites and systemic metabolic traits, highlighting disease progression‐associated pathways.